Testing a new therapy to reduce severe lung injury in patients with Acute Respiratory Distress Syndrome.
Official title: A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial
Funded at Aqualung Therapeutics Corp. · NIH-10925146 · Data updated 2026-11-12
This study is testing a new treatment for Acute Respiratory Distress Syndrome (ARDS) using a special antibody called ALT-100 mAb, which aims to help reduce lung inflammation and improve recovery for patients with this condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aqualung Therapeutics Corp. NIH-funded |
| Lab location | 1 site (Juno Beach, UNITED STATES) |
| Project start | June 1, 2019 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $957,594 |
| NIH project number | 5R44HL145930-05 |
| Project ID | NIH-10925146 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with Acute Respiratory Distress Syndrome, particularly those affected by conditions like COVID-19.
✕Less likely to help
Patients with mild respiratory issues or those not diagnosed with ARDS may not benefit from this research.
What this research studies
This research investigates a novel treatment for Acute Respiratory Distress Syndrome (ARDS) using a humanized monoclonal antibody called ALT-100 mAb. The therapy targets a specific protein, eNAMPT, which is involved in inflammation and lung injury. By neutralizing eNAMPT, the treatment aims to reduce the severity of ARDS and improve patient outcomes. The research includes a clinical trial where patients will receive this therapy to assess its safety and effectiveness.
Why it matters
Potential benefit: If successful, this research could significantly reduce mortality and improve recovery rates for patients suffering from ARDS.
How similar studies have gone: Previous research has shown promise in targeting eNAMPT for reducing inflammation in ARDS, suggesting a potential for success in this novel approach.
Where this research is happening
-
Aqualung Therapeutics Corp.
Juno Beach, United States Active
Researchers
- Principal investigator: Garcia, Joe G. N. — Aqualung Therapeutics Corp.
- Study coordinator: Garcia, Joe G. N.
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.